VFA
RGLS

Virtus Fund Advisers’s Regulus Therapeutics RGLS Stock Holding History

Virtus Fund Advisers’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-10
Closed -$9K – 1764
2014
Q2 		$9K Buy
+10
New +$8.57K ﹤0.01% 2778

Other funds holding RGLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
AWMDMG
Austin W. Marxe & David M. Greenhouse New York $733M AUM 21.72% 1-Year Est. Return

Virtus Fund Advisers's RGLS Position: Q3 2014 in Review

Virtus Fund Advisers sold out of Regulus Therapeutics (RGLS) in Q3 2014, closing a stake of 10 shares — an estimated $9K sold.

Virtus Fund Advisers first reported a position in RGLS in Q2 2014 and held it in 1 quarter. The position peaked at $9K in Q2 2014. 49 funds tracked by Wall St. Rank hold RGLS as of Q3 2014.

  • Virtus Fund Advisers reported no remaining Regulus Therapeutics position as of Q3 2014 after selling out during the quarter.
  • Virtus Fund Advisers sold 10 Regulus Therapeutics shares in Q3 2014, an estimated $9K.
  • Virtus Fund Advisers first reported a position in Regulus Therapeutics in Q2 2014 and held it in 1 quarter.
  • Virtus Fund Advisers's Regulus Therapeutics position peaked at $9K in Q2 2014.
  • 49 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q3 2014.

Based on Virtus Fund Advisers's 13F filing for Q3 2014, filed 31 Oct 2014.